Skip to main content

Latest

investment ideas
Deals, data buzz could help biotech shares exit Wall Street’s ‘no man’s land’
report on business
Field Trip Health raises largest financing in Canada for a psychedelics company
report on business
B.C.’s Eupraxia Pharmaceuticals sees lacklustre trading debut
advisor etfs
Why the nascent psychedelics industry is getting investors’ attention
report on business
First TSX-only biotech IPO in 18 years set for next week as Eupraxia closes books on $41-million offering
report on business
Vancouver biotech Notch Therapeutics raises US$85-million in venture funding
report on business
TMX CEO aims to encourage small biotech companies to list in Canada
report on business
RBC taps into biotech surge, investing in new Lumira venture fund
report on business
Vancouver’s Khosrowshahi family to launch US$400-million pharma IPO, capitalizing on biotech craze
report on business
Rare milestone approaches for Canadian biotech sector as Aurinia awaits FDA OK to sell new drug
report on business
AbCellera Biologics’s billionaire boss planning hiring spree in Vancouver hometown after record-setting IPO
opinion
What Canada needs to do to build a world-class biotech sector
Roberto Bellini
report on business
AbCellera closes record biotech IPO as underwriters exercise option to buy shares; total proceeds US$555.5-million
number cruncher
Which of these top 10 Canadian biotech stocks are undervalued?
international business
AstraZeneca shares fall as investors react to $39-billion Alexion acquisition
international business
AstraZeneca to buy U.S. drugmaker Alexion for $39-billion to expand in immunology
report on business
Vancouver’s AbCellera more than doubles IPO target size, headed for biggest debut on record for Canadian biotech
investment ideas
Cowen’s CEO sees gains in biotech, helped by easier access to cash
report on business
Booming Canadian biotech sector on track for record year after raising $1-billion in venture capital so far in 2020
report on business
Peter Thiel joins board of B.C. antibody therapy developer AbCellera in advance of expected IPO
report on business
Canada’s Pascal Biosciences partners with U.S. firm to test cannabis-based cancer therapy
report on business
Antibody therapy developer AbCellera hires banks for U.S. IPO, sources day
international business
Sanofi snags another U.S. biotech firm with $3.7-billion Principia deal
international business
CureVac doesn’t rule out accelerated approval for COVID-19 vaccine
advisor mutual funds
Active management finds niche in post-pandemic market
report on business
Vancouver COVID-19 therapy developer AbCellera eyeing potential IPO as early as fall
stars and dogs
The Globe’s stars and dogs for the week
letters
July 9: ‘The government of the people, by Justin Trudeau, for the people.’ Readers take a closer look at the WE Charity contract, plus other letters to the editor
streetwise newsletter
Streetwise newsletter: Best reads of the week
report on business
Biotech blind spot: How Canada’s big investors missed the boom happening right now
inside the market
Top Canadian biotech investor on the firms most likely to turn COVID-19 drug trials into treatments and when a vaccine may arrive
stars and dogs
The Globe’s stars and dogs for the week
science
BioNTech and Pfizer’s COVID-19 vaccine shows potential in human trial
european business
Temasek-led investor group makes $250-million vaccine bet on Germany’s BioNTech
technology
Hamilton biotech Fusion sets IPO price at $17 a share for Friday debut on Nasdaq